Skip to main content
SpringerLink
Log in

The Evidence Base for Combination Therapy

  • Chapter
  • First Online:
Combination Therapy in Hypertension

  • 599 Accesses

Abstract

Many clinical studies have shown that treating elevated systolic blood pressure results in a significant reduction in cardiovascular morbidity and mortality; however, multiple drug therapy is required in the majority of patients to achieve the current goals for blood pressure control. The use of combination therapy may result in greater decreases in systolic blood pressure, a higher rate of control of blood pressure, and a better adverse event profile than do component monotherapies at the same or higher doses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Chobanian AV, Bakris GL, Black HR, et al., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206–52.

    Google Scholar 

  • Guidelines Committee: 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011–53.

    Google Scholar 

  • Unger T, McInnes GT, Neutel JM, Böhm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 2004; 64(24):2731–9.

    Google Scholar 

  • Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20:671–81.

    Google Scholar 

  • Neutel JM, Saunders E, Bakris GL, et al., INCL USI VE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCL USI VE trial. J Clin Hypertens 2005; 7(10):578–86.

    Google Scholar 

  • Sowers JR, Neutel JM, Saunders E, et al., INCL USI VE Investigators. Antihypertensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens 2006; 8(7):470–80.

    Google Scholar 

  • Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan/HCT Z fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006; 98(4):618–26.

    Google Scholar 

  • Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8(12):850–7; quiz 858–9.

    Google Scholar 

  • Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22:266–74.

    Google Scholar 

  • Neutel JM, Klein C, Meinicke TW, Schumacher H. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11(5):302–9.

    Google Scholar 

  • White WB, Weber MA, Davidai G, Neutel JM, Bakris GL, Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT -2 Trial. Blood Press Monit 2005; 10(3):157–63.

    Google Scholar 

  • Lacourcière Y, Poirier L, Lefebvre J. Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. Can J Cardiol 2007; 23(5):377–82.

    Google Scholar 

  • Neutel JM, Smith DH, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens 2004; 6(4):168–74.

    Google Scholar 

  • Izzo JL, Neutel JM, Silfani T, Dubiel R, Walker F. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007; 9(1):36–44.

    Google Scholar 

  • Izzo JL, Neutel JM, Silfani T, Dubiel R, Walker F. Titration of HCT Z to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens 2007; 9(1):45–8.

    Google Scholar 

  • Izzo J, Neutel J, Dubiel R, Walker F. Metabolic effects and safety of hydrochlorothiazide (HCT Z) in combination with olmesartan medoxomil (OLM) in stage 2 systolic hypertension (HTN). Am J Hypertens 2005; 18 (5 Pt 2):64A. Posters: Antihypertensive drugs and pharmacology. P-159.

    Google Scholar 

  • Ruoff G. ACE inhibitors and diuretics. The benefits of combined therapy for hypertension. Postgrad Med 1989; 85(3):127–32, 137–9.

    Google Scholar 

  • Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M; investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a steppedcare approach. J Hypertens 2004; 22(12):2379–86.

    Google Scholar 

  • PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24:475–84.

    Google Scholar 

  • Chapman N, Huxley R, Anderson C, et al; Writing Committee for the PRO GRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PRO GRESS Trial. Stroke 2004; 35:116–21. Epub 2003 Dec 11.

    Google Scholar 

  • Morisco C, Lembo G, Sarno D, et al. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. J Cardiovasc Pharmacol 1998; 31(Suppl 2):S27–33.

    Google Scholar 

  • Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002; 15(6):550–6.

    Google Scholar 

  • Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17(1):37–42.

    Google Scholar 

  • Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol 2006; 15(3):142–50.

    Google Scholar 

  • Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens 2005; 7(11):641–6; quiz 647–8.

    Google Scholar 

  • Neutel JM, Smith DH, Weber MA, Nwose OM, Schofield L, Gatlin M. Management of isolated vs. predominantly systolic hypertension: results of the systolic evaluation of Lotrel efficacy and comparative therapies (SELECT) study. Am J Hypertens 2004; 17:184A (poster P -411).

    Google Scholar 

  • Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597–603.

    Google Scholar 

  • Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Diabetes Care 1998; 21:655–7.

    Google Scholar 

  • Pahor M, Tatti P. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies. Am J Cardiol 1999; 83:819–20.

    Google Scholar 

  • Sowers JR. Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET). Am J Cardiol 1998; 82(9B):15–19R.

    Google Scholar 

  • Chrysant SG. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Drugs Today (Barc) 2008; 44(6):443–53.

    Google Scholar 

  • Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008; 10(1 Suppl 1):27–32.

    Google Scholar 

  • Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008; 25(5): 399–411.

    Google Scholar 

  • Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29(4):563–80.

    Google Scholar 

  • Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 2008; 68(3):373–81.

    Google Scholar 

  • Krzesinski JM, Scheen AJ. [A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge.] [Article in French.] Rev Med Liege 2007; 62(11):688–94.

    Google Scholar 

  • Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007; 9(5):355–64.

    Google Scholar 

  • Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29(2):279–89.

    Google Scholar 

  • Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30(4):587–604.

    Google Scholar 

  • Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008; 10(3):185–94.

    Google Scholar 

  • Fogari R, Zoppi A, Mugellini A, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr. Epub ahead of print 2008 May 3.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine, Orange County Research Center, Tustin, CA, USA

    Joel Neutel

Authors
  1. Joel Neutel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Neutel .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Healthcare

About this chapter

Cite this chapter

Neutel, J. (2011). The Evidence Base for Combination Therapy. In: Combination Therapy in Hypertension. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-28-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-28-9_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-25-8

  • Online ISBN: 978-1-908517-28-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation